SERPINA1 and COVID-19: Other than having a genetic deficiency of AAT, studies have also suggested that during the course of COVID-19 illness, patients may develop an insufficient AAT acute-phase response in severe COVID-19 illness, which may ultimately increase disease severity and risk of mortality [162].